M-END PE (BROMPHENIRAMINE MALEATE/PHENYLEPHRINE HCL/CODEINE PHOS)

Contraindicated



• Depade
• isocarboxazid
• Marplan
• Matulane
• methylene blue (antidote)
• naltrexone
• naltrexone microspheres
• Nardil
• Parnate
• phenelzine
• procarbazine
• Revia
• tranylcypromine
• Vivitrol

Severe



• Azilect
• bromocriptine
• cabergoline
• Cafergot
• Compound 347
• Cycloset
• D.h.e.45
• dihydroergotamine
• Eldepryl
• enflurane
• ergoloid
• Ergomar
• ergotamine tartrate
• ergotamine-caffeine
• Forane
• isoflurane
• linezolid
• methylergonovine
• Migergot
• Migranal
• Parlodel
• rasagiline
• selegiline HCl
• sevoflurane
• Sojourn
• Terrell
• Ultane
• Zelapar
• Zyvox

Contraindicated



• Acute myocardial infarction
• Adenoidectomy in pediatric patient
• Arterial thrombosis
• Lactating mother
• Respiratory depression
• Severe uncontrolled hypertension
• Sleep apnea
• Tonsillectomy in pediatric patient
• Ventricular tachycardia

Severe



• Acute asthma attack
• Acute hepatitis
• Acute pancreatitis
• Angle-closure glaucoma
• Asthma
• Benign prostatic hyperplasia
• Bladder outflow obstruction
• Bradycardia
• Chronic idiopathic constipation
• Chronic obstructive pulmonary disease
• Coronary artery disease
• CYp2d6 poor metabolizer
• CYp2d6 ultrarapid metabolizer
• Drug abuse
• Gastrointestinal obstruction
• History of opioid overdose
• Hypertension
• Hyperthyroidism
• Incomplete AV heart block
• Intracranial hypertension
• Kidney disease with likely reduction in GFR
• Obstructive sleep apnea syndrome
• Severe arteriosclerotic vascular disease
• Shock
• Stenosing peptic ulcer
• Systemic mastocytosis
• Urinary retention

Contraindicated

Brompheniramine

Possible CNS excitation, convulsions in newborns.

Risk of serious and life-threatening adverse effects of CNS depression or excitation. Not recommended age <2 years. Avoid using with underlying asthma.

Not indicated for symptoms of cough and cold in pediatrics. Risk of slowed or difficult breathing and respiratory depression. Death reported in CYP2D6 ultra-rapid metabolizers post tonsillectomy or adenoidectomy.

Risk of CNS excitation. Do not use age <6 years without clinician consult.

• 1 Day – 29 Days
• 1 Possible CNS excitation, convulsions in newborns.
• 1 Risk of serious and life-threatening adverse effects of CNS depression or excitation. Not recommended age <2 years. Avoid using with underlying asthma.
• 30 Days – 2 Years
• 1 Possible CNS excitation, convulsions in newborns.
• 1 Risk of serious and life-threatening adverse effects of CNS depression or excitation. Not recommended age <2 years. Avoid using with underlying asthma.
• 1 Day – 18 Years
• 1 Possible CNS excitation, convulsions in newborns.
• 1 Risk of serious and life-threatening adverse effects of CNS depression or excitation. Not recommended age <2 years. Avoid using with underlying asthma.
• 1 Day – 6 Years
• 1 Possible CNS excitation, convulsions in newborns.
• 1 Risk of serious and life-threatening adverse effects of CNS depression or excitation. Not recommended age <2 years. Avoid using with underlying asthma.

Codeine (cough_cold)

Possible CNS excitation, convulsions in newborns.

Risk of serious and life-threatening adverse effects of CNS depression or excitation. Not recommended age <2 years. Avoid using with underlying asthma.

Not indicated for symptoms of cough and cold in pediatrics. Risk of slowed or difficult breathing and respiratory depression. Death reported in CYP2D6 ultra-rapid metabolizers post tonsillectomy or adenoidectomy.

Risk of CNS excitation. Do not use age <6 years without clinician consult.

• 1 Day – 29 Days
• 1 Not indicated for symptoms of cough and cold in pediatrics. Risk of slowed or difficult breathing and respiratory depression. Death reported in CYP2D6 ultra-rapid metabolizers post tonsillectomy or adenoidectomy.
• 30 Days – 2 Years
• 1 Not indicated for symptoms of cough and cold in pediatrics. Risk of slowed or difficult breathing and respiratory depression. Death reported in CYP2D6 ultra-rapid metabolizers post tonsillectomy or adenoidectomy.
• 1 Day – 18 Years
• 1 Not indicated for symptoms of cough and cold in pediatrics. Risk of slowed or difficult breathing and respiratory depression. Death reported in CYP2D6 ultra-rapid metabolizers post tonsillectomy or adenoidectomy.
• 1 Day – 6 Years
• 1 Not indicated for symptoms of cough and cold in pediatrics. Risk of slowed or difficult breathing and respiratory depression. Death reported in CYP2D6 ultra-rapid metabolizers post tonsillectomy or adenoidectomy.

Phenylephrine (oral)

Possible CNS excitation, convulsions in newborns.

Risk of serious and life-threatening adverse effects of CNS depression or excitation. Not recommended age <2 years. Avoid using with underlying asthma.

Not indicated for symptoms of cough and cold in pediatrics. Risk of slowed or difficult breathing and respiratory depression. Death reported in CYP2D6 ultra-rapid metabolizers post tonsillectomy or adenoidectomy.

Risk of CNS excitation. Do not use age <6 years without clinician consult.

• 1 Day – 29 Days
• 1 Risk of CNS excitation. Do not use age <6 years without clinician consult.
• 30 Days – 2 Years
• 1 Risk of CNS excitation. Do not use age <6 years without clinician consult.
• 1 Day – 18 Years
• 1 Risk of CNS excitation. Do not use age <6 years without clinician consult.
• 1 Day – 6 Years
• 1 Risk of CNS excitation. Do not use age <6 years without clinician consult.

Severe Precaution

Brompheniramine

Risk of CNS excitation and respiratory depression. Avoid using with underlying asthma. Consult healthcare provider.

• 2 Years – 6 Years
• Risk of CNS excitation and respiratory depression. Avoid using with underlying asthma. Consult healthcare provider.

Management or Monitoring Precaution

None